Flurazepam
| Flurazepam | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 387.90 g/mol [1] |
| Appearance | White rods from ether-petroleum ether [1] |
| Melting point | 190-220 [1] |
| Solubility | 500 mg/mL (HCl salt) [1] |
| Predicted LogP | 3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C21H23ClFN3O |
| IUPAC name | 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one |
| SMILES | CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F |
| InChI | InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3 |
| InChIKey | SAADBVWGJQAEFS-UHFFFAOYSA-N |
| CAS number | 17617-23-1 |
| UNII | IHP475989U |
| PubChem CID | 3393 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 2.3 hours, N-desalkylflurazepam: 47–100 hours |
| Metabolism | Liver |
| Excretion | Kidney |
| Routes of administration | By mouth |
| Addiction liability | Moderate |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - ip: 290 mg/kg - oral: 870 mg/kg - iv: 84 mg/kg [1] |
Flurazepam (also known as Insumin, Flurazepamum, Dalmane-R, Felison, Ro-5-6901/3, Dormodor, Apo Flurazepam, Flurazepam Mono Perchlorate, Mono-Perchlorate, Flurazepam or N05cd01) is a substance of the aniline and benzodiazepine class.
Chemistry
Stereochemistry []
Flurazepam is achiral.
Druglikeness
Lipinski's rule of five
Flurazepam matches Lipinski's rule of five.Reagents
There are currently 2 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Froehde | orange | |
| Zimmermann | violet / purple |
Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- hypnotics and sedatives (N05C)
- benzodiazepine derivatives (N05CD)
- flurazepam (N05CD01)
MeSH Classification
Mechanism of action []
Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| GABRA1 | shared target | 37 |
|---|---|---|
| GABRA2 | shared target | 34 |
| GABRA3 | shared target | 34 |
| GABRA4 | shared target | 34 |
| GABRA5 | shared target | 34 |
| GABRA6 | shared target | 34 |
| GABRB1 | shared target | 34 |
| GABRB2 | shared target | 34 |
| GABRB3 | shared target | 34 |
| GABRD | shared target | 34 |
| GABRE | shared target | 34 |
| GABRG1 | shared target | 34 |
| GABRG2 | shared target | 34 |
| GABRG3 | shared target | 34 |
| GABRP | shared target | 34 |
| GABRQ | shared target | 34 |
Medical side effects []
59 side effects listed on drug labels in SIDER 4.1 (flurazepam).
- Agranulocytosis
- Decreased appetite
- Arthralgia
- Musculoskeletal discomfort
- Asthenia
- Ataxia
- Chest pain
- Coma
- Confusional state
- Feeling abnormal
- Constipation
- Diarrhoea
- Dizziness
- Syncope
- Lightheadedness
- Somnolence
- Dyspnoea
- Dermatitis
- Rash
- Flushing
- Hallucination
- Headache
- Dyspepsia
- Hypotension
- Irritability
- Lethargy
- Leukopenia
- Nausea
- Nervousness
- Tension
- Palpitations
- Pruritus
- Salivary hypersecretion
- Withdrawal syndrome
- Hyperhidrosis
- Shock
- Loss of consciousness
- Vomiting
- Dry mouth
- Agitation
- Excitement
- Hyperkinesia
- Blood alkaline phosphatase increased
- Aspartate aminotransferase increased
- Disorientation
- Anxiety
- Thinking abnormal
- Mental disability
- Dysarthria
- Euphoric mood
- Dysgeusia
- Abdominal discomfort
- Drug intolerance
- Anaphylactic shock
- Anaphylactoid reaction
- Vision blurred
- Gastrointestinal pain
- Gait disturbance
- Logorrhoea
Indications
- Insomnia
- Terminal insomnia
Subjective effects []
| nervewing / Flurazepam [] | |
|---|---|
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3393, Flurazepam. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3393
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Flurazepam. UNII: IHP475989U. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/IHP475989U
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. Läkemedelsverket. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 18:00:26 |
| drugspro | ok | 2026-11-20 18:00:22 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 18:00:22 |
| gsrs | ok | 2026-11-20 18:00:22 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014828) | 2026-11-20 18:00:22 |
| kegg | ok | 2026-11-20 18:00:24 |
| pubchem | ok | 2026-11-20 18:00:21 |
| missing (no r/tripreports posts mention it) | 2026-11-20 18:00:22 | |
| sider | ok | 2026-11-20 18:00:22 |
| structure | ok | 2026-11-20 18:00:22 |
| wikipedia | ok | 2026-11-20 18:00:22 |